Experienced leaders will spearhead operations and client services at the new U.S. headquarters and laboratory
MARTINSRIED-MUNICH, Germany, October 07, 2025 / Biotech Newswire / -- Coriolis Pharma today announced the next step in its U.S. expansion by strengthening its team in North Carolina with the appointment of John Gabrielson as President of Coriolis Pharma US Inc. and Amber Raines as Senior Director, Client Project Management.
In his role as President of Coriolis Pharma US Inc., John will lead the establishment of the new U.S. Headquarters and Laboratory, working closely with a highly skilled team to scale operations and build a strong foundation for future growth. He will play a pivotal role in executing Coriolis Pharma’s strategic vision and ensuring the successful rollout of service offerings tailored to the specific needs of the U.S. market. John brings over 20 years of experience in biologics development, having held senior leadership roles at both biotech companies and CDMOs. His expertise spans CMC planning, analytical sciences, and organizational strategy. John’s impressive track record includes founding Elion Labs and Similis Bio, leading large scientific teams in companies like KBI Biopharma and Amgen and contributing to the development and approval of more than 100 novel and biosimilar therapeutics.
Amber Raines joins the U.S. commercial team as Senior Director, Client Project Management, where she will lead the client project management group. With her deep scientific expertise and strong background in pharmaceutical development, Amber will ensure the successful execution of client projects and serve as a key interface between clients and internal teams. Amber brings extensive experience in pharmaceutical development and project leadership. She previously served as Senior Director Rapid Analytics at KBI Biopharma in Louisville, Colorado, and held roles including Director of the Particle Characterization Core Facility at KBI Biopharma. Before, she held various positions at KBI Biopharma, Amgen, and Merck & Co., among others.
“With John and Amber, we are gaining two outstanding professionals who share our vision and will play a key role in strengthening our presence in the U.S. market,” says Silvia Steyrer-Gruber, CEO of Coriolis Pharma. “Their leadership and deep expertise make them a perfect fit for Coriolis. As we expand our footprint in the U.S. their contributions will be instrumental in launching our operational activities at the new laboratory and headquarters, and enabling us to offer our on-site services to our clients early next year.”
For high resolution please click the images.
About Coriolis Pharma
Coriolis Pharma is a globally operating contract research and development organization (CRDO) and the premier partner for drug product development, analytical services and manufacturing services across a vast array of biological therapeutic modalities. With a focus on liquid and lyophilized drug products, Coriolis expert scientists design and execute platform and custom services to accelerate and derisk client programs right from the start and throughout the entire product lifecycle.
Headquartered in Martinsried near Munich, the company offers tailored solutions from early development stages to market approval. Coriolis Pharma stands out for its scientific excellence, innovative analytical methods, and deep understanding of formulation and drug product development.
With the establishment of its new laboratory and U.S. headquarters in North Carolina, Coriolis Pharma is expanding its global footprint and bringing its high-quality services closer to clients in the United States.
Contact
Coriolis Pharma
Bettina von Klitzing-Stückle
Marketing Manager
+49 (0) 89 4177 60 – 0
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Leadership; Appointments and Schedules; Drug Delivery Systems; Drug Development; Drug Compounding; Laboratories; Biological Products; Pharmaceutical Preparations; Biotechnology; Coriolis Pharma; U.S. expansion; North Carolina; John Gabrielson; Coriolis Pharma US Inc.; Amber Raines; biologics development; CDMOs; Silvia Steyrer-Gruber; contract research and development organization (CRDO); drug product development; analytical services; manufacturing services; biological therapeutic modalities; liquid drug products; lyophilized drug products; formulation development
Source: Biotech Newswire